Philipp Von Rosenstiel

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.

Journal: Epilepsia
Published: October 16, 2025

A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.

A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.

Journal: Epilepsia
Published: October 16, 2025

Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.

Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.

Journal: The New England journal of medicine
Published: May 14, 2025

TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation without Affecting Analgesia in Healthy Men.

TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation without Affecting Analgesia in Healthy Men.

Journal: Anesthesiology
Published: January 13, 2025

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.

Journal: The New England journal of medicine
Published: July 26, 2023

Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.

Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: June 05, 2023

Advancing combination therapy for Alzheimer's disease.

Advancing combination therapy for Alzheimer's disease.

Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 09, 2020

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

Journal: The journal of prevention of Alzheimer's disease
Published: November 29, 2017

Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.

Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.

Journal: Epilepsia
Published: November 05, 2015

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.

Journal: Journal of neurology
Published: June 23, 2015

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: February 25, 2015

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.

Journal: Neurology
Published: February 01, 2015
Showing 1-12 of 25

Last Updated: 09/26/2026